vs
Side-by-side financial comparison of Bank of Marin Bancorp (BMRC) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $34.1M, roughly 1.8× Bank of Marin Bancorp). Bank of Marin Bancorp runs the higher net margin — 24.9% vs -92.6%, a 117.5% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 23.3%).
American River Bank was a community bank founded in 1983 by Robert H. Daneke, who served as first president and CEO, and Bill L. Withrow, the first Chairman of the Board, and served the Greater Sacramento area in California. As of 2019, It operated ten branches in Northern CA. American River Bank which offered both business and personal financial services and was a wholly owned subsidiary of American River Bankshares.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
BMRC vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $60.1M |
| Net Profit | $8.5M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | — | -87.1% |
| Net Margin | 24.9% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | 74.5% | — |
| EPS (diluted) | $0.53 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $34.1M | $60.1M | ||
| Q4 25 | $27.0M | $57.3M | ||
| Q3 25 | $30.9M | $51.3M | ||
| Q2 25 | $10.3M | $48.5M | ||
| Q1 25 | $27.8M | $32.7M | ||
| Q4 24 | $22.2M | $41.8M | ||
| Q3 24 | $27.2M | $33.3M | ||
| Q2 24 | $22.5M | $29.1M |
| Q1 26 | $8.5M | $-55.6M | ||
| Q4 25 | $-39.5M | $-47.5M | ||
| Q3 25 | $7.5M | $-52.9M | ||
| Q2 25 | $-8.5M | $-46.6M | ||
| Q1 25 | $4.9M | $-49.5M | ||
| Q4 24 | $6.0M | $-43.3M | ||
| Q3 24 | $4.6M | $-43.6M | ||
| Q2 24 | $-21.9M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | -212.6% | -82.2% | ||
| Q3 25 | 31.1% | -102.6% | ||
| Q2 25 | -108.8% | -93.4% | ||
| Q1 25 | 23.3% | -143.7% | ||
| Q4 24 | 43.5% | -98.6% | ||
| Q3 24 | 25.7% | -132.0% | ||
| Q2 24 | -153.0% | -139.2% |
| Q1 26 | 24.9% | -92.6% | ||
| Q4 25 | -146.5% | -83.0% | ||
| Q3 25 | 24.3% | -103.1% | ||
| Q2 25 | -82.9% | -96.1% | ||
| Q1 25 | 17.5% | -151.4% | ||
| Q4 24 | 27.1% | -103.6% | ||
| Q3 24 | 16.8% | -131.2% | ||
| Q2 24 | -97.5% | -110.9% |
| Q1 26 | $0.53 | $-0.83 | ||
| Q4 25 | $-2.48 | $-0.73 | ||
| Q3 25 | $0.47 | $-0.82 | ||
| Q2 25 | $-0.53 | $-0.75 | ||
| Q1 25 | $0.30 | $-0.81 | ||
| Q4 24 | $0.38 | $-0.71 | ||
| Q3 24 | $0.28 | $-0.73 | ||
| Q2 24 | $-1.36 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $394.5M | $122.9M |
| Total Assets | $3.9B | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | $394.5M | $122.9M | ||
| Q4 25 | $394.7M | $139.1M | ||
| Q3 25 | $443.8M | $148.8M | ||
| Q2 25 | $438.5M | $-11.9M | ||
| Q1 25 | $439.6M | $18.9M | ||
| Q4 24 | $435.4M | $21.7M | ||
| Q3 24 | $437.0M | $11.2M | ||
| Q2 24 | $434.9M | $39.3M |
| Q1 26 | $3.9B | $442.3M | ||
| Q4 25 | $3.9B | $480.2M | ||
| Q3 25 | $3.9B | $506.9M | ||
| Q2 25 | $3.7B | $372.7M | ||
| Q1 25 | $3.8B | $386.7M | ||
| Q4 24 | $3.7B | $392.3M | ||
| Q3 24 | $3.8B | $363.6M | ||
| Q2 24 | $3.7B | $381.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMRC
| Net Interest Income | $30.3M | 89% |
| Noninterest Income | $3.8M | 11% |
RYTM
Segment breakdown not available.
